Poster
I-DXd
ESMO Asia 2025 | December 5-7, 2025
Esophageal Cancer
IDeate-Esophageal01: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) in patients with pretreated advanced/metastatic esophageal squamous cell carcinoma
Ken Kato